The Effects of the COVID-19 Pandemic in Oncology Patient Management
Abstract
:1. Introduction
2. Materials and Methods
2.1. Inclusion and Exclusion Criteria
2.2. Patient and Public Involvement
3. Results
4. Discussion
5. Conclusions
Study Limitations
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Abbreviations
Appendix A
References
- Miaskowski, C.; Paul, S.M.; Snowberg, K.; Abbott, M.; Borno, H.; Chang, S.; Chen, L.M.; Cohen, B.; Cooper, B.A.; Hammer, M.J.; et al. Oncology patients’ perceptions of and experiences with COVID-19. Support Care Cancer 2021, 29, 1941–1950. [Google Scholar] [CrossRef] [PubMed]
- Curigliano, G.; Cardoso, M.J.; Poortmans, P.; Gentilini, O.; Pravettoni, G.; Mazzocco, K.; Houssami, N.; Pagani, O.; Senkus, E.; Cardoso, F. Recommendations for triage, prioritization and treatment of breast cancer patients during the COVID-19 pandemic. Breast 2020, 52, 8–16. [Google Scholar] [CrossRef] [PubMed]
- Mollica, V.; Rizzo, A.; Massari, F. The pivotal role of TMPRSS2 in coronavirus disease 2019 and prostate cancer. Future Oncol. 2020, 16, 2029–2033. [Google Scholar] [CrossRef] [PubMed]
- Moujaess, E.; Kourie, H.R.; Ghosn, M. Cancer patients and research during COVID-19 pandemic: A systematic review of current evidence. Crit. Rev. Oncol. Hematol. 2020, 150, 102972. [Google Scholar] [CrossRef]
- Pathania, A.S.; Prathipati, P.; Abdul, B.A.; Chava, S.; Katta, S.S.; Gupta, S.C.; Gangula, P.R.; Pandey, M.K.; Durden, D.L.; Byrareddy, S.N.; et al. COVID-19 and cancer comorbidity: Therapeutic opportunities and challenges. Theranostics 2020, 11, 731–753. Available online: https://pubmed.ncbi.nlm.nih.gov/33391502/ (accessed on 26 October 2021). [CrossRef]
- Rizzo, A.; Palmiotti, G. SARS-CoV-2 Omicron variant in cancer patients: An insight into the vaccine booster debate. Future Oncol. 2022, 18, 1301–1302. [Google Scholar] [CrossRef]
- Shahidsales, S.; Aledavood, S.A.; Joudi, M.; Molaie, F.; Esmaily, H.; Javadinia, S.A. COVID-19 in cancer patients may be presented by atypical symptoms and higher mortality rate, a case-controlled study from Iran. Cancer Rep. 2021, 4, e1378. Available online: https://pubmed.ncbi.nlm.nih.gov/33742793/ (accessed on 11 July 2022). [CrossRef]
- Taghizadeh-Hesary, F.; Porouhan, P.; Soroosh, D.; PeyroShabany, B.; Shahidsales, S.; Keykhosravi, B.; Rahimi, F.; Houshyari, M.; Forouzanfar, M.M.; Javadinia, S.A. COVID-19 in cancer and non-cancer patients. Int. J. Cancer Manag. 2021, 14, e110907. [Google Scholar] [CrossRef]
- Javadinia, S.A.; Ariamanesh, M.; Nabavifard, M.; Porouhan, P.; PeyroShabany, B.; Fazilat-Panah, D.; Hatami, F.; Ghasemi, A.; Lyman, G.H.; Welsh, J.S.; et al. Multicenter Study of Antibody Seroprevalence against COVID-19 in Patients Presenting to Iranian Cancer Centers after One Year of the COVID-19 Pandemic. Cancer Investig. 2022, 40, 115–123. [Google Scholar] [CrossRef]
- Aapro, M.; Lyman, G.H.; Bokemeyer, C.; Rapoport, B.L.; Mathieson, N.; Koptelova, N.; Cornes, P.; Anderson, R.; Gascón, P.; Kuderer, N.M. Supportive care in patients with cancer during the COVID-19 pandemic. ESMO Open 2021, 6, 100038. [Google Scholar] [CrossRef]
- Instituto Nacional de Estatística. Mortalidade por COVID-19 Mais Elevada e Prematura nos Homens—2020. 2022. Available online: https://www.ine.pt/xportal/xmain?xpid=INE&xpgid=ine_destaques&DESTAQUESdest_boui=540774816&DESTAQUEStema=55538&DESTAQUESmodo=2 (accessed on 18 July 2022).
- Instituto Nacional de Estatística. Conta Satélite da Saúde: Recomposição da Despesa Corrente em Saúde com o Reforço da Despesa Pública e Redução da Despesa Privada no Contexto da Pandemia—2020. 2022. Available online: https://www.ine.pt/xportal/xmain?xpid=INE&xpgid=ine_destaques&DESTAQUESdest_boui=473138405&DESTAQUEStema=55538&DESTAQUESmodo=2 (accessed on 18 July 2022).
- Instituto Nacional de Estatística. Quebras Sem Precedentes No Número de Atos Assistenciais Prestados em 2020–2022. 2022. Available online: https://www.ine.pt/xportal/xmain?xpid=INE&xpgid=ine_destaques&DESTAQUESdest_boui=536782138&DESTAQUEStema=55538&DESTAQUESmodo=2 (accessed on 18 July 2022).
- Instituto Nacional de Estatística (INE). Despesa corrente em saúde aumentou 12,2% em 2021, atingindo 11,2% do PIB – 2021. 2022. Available online: https://www.ine.pt/xportal/xmain?xpid=INE&xpgid=ine_destaques&DESTAQUESdest_boui=540875581&DESTAQUEStema=55538&DESTAQUESmodo=2 (accessed on 18 July 2022).
- Patel, R.; Park, J.; Shah, A.; Wasif Saif, M. COVID-19 and Cancer Patients. Cancer Med. J. 2020, 3, 40–48. [Google Scholar] [PubMed]
- Brunetti, O.; Derakhshani, A.; Baradaran, B.; Galvano, A.; Russo, A.; Silvestris, N. COVID-19 Infection in Cancer Patients: How Can Oncologists Deal With These Patients? Front. Oncol. 2020, 10, 734. [Google Scholar] [CrossRef] [PubMed]
- Ueda, M.; Martins, R.; Hendrie, P.C.; McDonnell, T.; Crews, J.R.; Wong, T.L.; McCreery, B.; Jagels, B.; Crane, A.; Byrd, D.R.; et al. Managing Cancer Care During the COVID-19 Pandemic: Agility and Collaboration Toward a Common Goal. J. Natl. Compr. Cancer Netw. 2020, 18, 366–369. [Google Scholar] [CrossRef] [Green Version]
- Aruru, M.; Truong, H.A.; Clark, S. Pharmacy Emergency Preparedness and Response (PEPR): A proposed framework for expanding pharmacy professionals’ roles and contributions to emergency preparedness and response during the COVID-19 pandemic and beyond. Res. Soc. Adm. Pharm. 2021, 17, 1967–1977. [Google Scholar] [CrossRef]
- Cannizzaro, R.; Puglisi, F. COVID-19 and cancer patients: Choosing wisely is the key. Dig. Liver Dis. 2020, 52, 595. [Google Scholar] [CrossRef]
- Vose, J.M. Delay in cancer screening and diagnosis during the COVID-19 pandemic: What is the cost? Oncology 2019, 34, 343. [Google Scholar]
- Rüthrich, M.M.; Giessen-Jung, C.; Borgmann, S.; Classen, A.Y.; Dolff, S.; Grüner, B.; Hanses, F.; Isberner, N.; Köhler, P.; Lanznaster, J.; et al. COVID-19 in cancer patients: Clinical characteristics and outcome—an analysis of the LEOSS registry. Ann. Hematol. 2021, 100, 383–393. [Google Scholar] [CrossRef]
- Porzio, G.; Cortellini, A.; Bruera, E.; Verna, L.; Ravoni, G.; Peris, F.; Spinelli, G. Home Care for Cancer Patients During COVID-19 Pandemic: The Double Triage Protocol. J. Pain Symptom. Manag. 2020, 60, e5–e7. [Google Scholar] [CrossRef]
- Brunello, A.; Galiano, A.; Finotto, S.; Monfardini, S.; Colloca, G.; Balducci, L.; Zagonel, V. Older cancer patients and COVID-19 outbreak: Practical considerations and recommendations. Cancer Med. 2020, 9, 9193–9204. [Google Scholar] [CrossRef]
- Ramakrishna, R.; Zadeh, G.; Sheehan, J.P.; Aghi, M.K. Inpatient and outpatient case prioritization for patients with neuro-oncologic disease amid the COVID-19 pandemic: General guidance for neuro-oncology practitioners from the AANS/CNS Tumor Section and Society for Neuro-Oncology. J. Neurooncol. 2020, 147, 525–529. [Google Scholar] [CrossRef] [Green Version]
- Conselho do Colégio de Especialidade de Farmácia Hospitalar. Plano de Contingência da Farmácia Hospitalar no âmbito da Pandemia COVID-19. 2020. Available online: https://www.ordemfarmaceuticos.pt/pt/noticias/plano-de-contingencia-para-a-farmacia-hospitalar/ (accessed on 26 October 2021).
- Amariles, P.; Ledezma-Morales, M.; Salazar-Ospina, A.; Hincapié-García, J.A. How to link patients with suspicious COVID-19 to health system from the community pharmacies? A route proposal. Res. Soc. Adm. Pharm. 2021, 17, 1988–1989. [Google Scholar] [CrossRef] [PubMed]
- Cancarevic, I.; Tathineni, P.; Malik, B.H. Coronavirus Disease 2019 (COVID-19) in Cancer Patients. Cureus 2020, 12, e7835. [Google Scholar] [CrossRef] [Green Version]
- Zhao, H.; Du, S.; Cai, J.; Mao, Y. Recommendations for medical care of oncological patients during the COVID-19 epidemic: Experiences from China. Updates Surg. 2020, 1, 3. [Google Scholar] [CrossRef] [PubMed]
- Liu, C.; Zhao, Y.; Okwan-Duodu, D.; Basho, R.; Cui, X. COVID-19 in cancer patients: Risk, clinical features, and management. Cancer Biology and Medicine. Chin. Anti-Cancer Assoc. 2020, 17, 519–527. [Google Scholar]
- Da Oncologia, S.P. Recomendações para o Tratamento de Doentes com Cancro e o COVID-19. 2020. Available online: https://www.sponcologia.pt/fotos/editor2/publicacoes/recomendacoes_para_o_tratamento.pdf (accessed on 26 October 2021).
- Hanna, T.P.; Evans, G.A.; Booth, C.M. Cancer, COVID-19 and the precautionary principle: Prioritizing treatment during a global pandemic. Nat. Rev. Clin. Oncol. 2020, 17, 268–270. [Google Scholar] [CrossRef]
- Omarini, C.; Maur, M.; Luppi, G.; Narni, F.; Luppi, M.; Dominici, M.; Longo, G.; Piacentini, F. Cancer treatment during the coronavirus disease 2019 pandemic: Do not postpone, do it! Eur. J. Cancer. 2020, 133, 29–32. [Google Scholar] [CrossRef]
- Banna, G.; Curioni-Fontecedro, A.; Friedlaender, A.; Addeo, A. How we treat patients with lung cancer during the SARS-CoV-2 pandemic: Primum non nocere. ESMO Open 2020, 5, 29–32. [Google Scholar] [CrossRef]
- Cadogan, C.A.; Hughes, C.M. On the frontline against COVID-19: Community pharmacists’ contribution during a public health crisis. Res. Soc. Adm. Pharm. 2021, 17, 2032–2035. [Google Scholar] [CrossRef]
- Zheng, S.Q.; Yang, L.; Zhou, P.X.; Li, H.B.; Liu, F.; Zhao, R.S. Recommendations and guidance for providing pharmaceutical care services during COVID-19 pandemic: A China perspective. Res. Soc. Adm. Pharm. 2021, 17, 1819–1824. [Google Scholar] [CrossRef]
- Javadinia, S.A.; Alizadeh, K.; Mojadadi, M.S.; Nikbakht, F.; Dashti, F.; Joudi, M.; Harati, H.; Welsh, J.S.; Farahmand, S.A.; Attarian, F. COVID-19 Vaccination in Patients With Malignancy; A Systematic Review and Meta-Analysis of the Efficacy and Safety. Front. Endocrinol. 2022, 13, 446. [Google Scholar] [CrossRef]
- Joudi, M.; Binabaj, M.M.; Porouhan, P.; PeyroShabany, B.; Tabasi, M.; Fazilat-Panah, D.; Khajeh, M.; Mehrabian, A.; Dehghani, M.; Welsh, J.S.; et al. A Cohort Study on the Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients With Breast Cancer; Does Trastuzumab Interfere With the Outcome? Front. Endocrinol. 2022, 13, 1. [Google Scholar] [CrossRef] [PubMed]
- Ariamanesh, M.; Porouhan, P.; PeyroShabany, B.; Fazilat-Panah, D.; Dehghani, M.; Nabavifard, M.; Hatami, F.; Fereidouni, M.; Welsh, J.S.; Javadinia, S.A. Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients with Malignancy. Cancer Investig. 2022, 40, 26–34. [Google Scholar] [CrossRef] [PubMed]
- Wang, D.; Hu, B.; Hu, C.; Zhu, F.; Liu, X.; Zhang, J.; Wang, B.; Xiang, H.; Cheng, Z.; Xiong, Y.; et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA—J. Am. Med. Assoc. 2020, 323, 1061–1069. [Google Scholar] [CrossRef] [PubMed]
Recommendation | Healthcare Professional (N = 33) | N | Mean Rank | Response Rate for Developed Recommendation (%) | Mann–Whitney U-Test | p Value |
---|---|---|---|---|---|---|
| Nurse | 18 | 15.58 | 63.6 | 109,500 | 0.361 |
Physician | 15 | 18.70 | ||||
| Nurse | 18 | 14.08 | 54.5 | 82,500 | 0.057 |
Physician | 15 | 20.50 | ||||
| Nurse | 18 | 17.75 | 54.5 | 148,500 | 0.630 |
Physician | 15 | 16.10 | ||||
| Nurse | 18 | 16.33 | 51.5 | 123,000 | 0.682 |
Physician | 15 | 17.80 | ||||
| Nurse | 18 | 14.50 | 51.5 | 90,000 | 0.108 |
Physician | 15 | 20.00 | ||||
| Nurse | 18 | 18.00 | 39.4 | 153,000 | 0.532 |
Physician | 15 | 15.80 | ||||
| Nurse | 18 | 13.75 | 30.3 | 76,500 | 0.033 |
Physician | 15 | 20.90 | ||||
| Nurse | 18 | 16.00 | 27.3 | 117,000 | 0.532 |
Physician | 15 | 18.20 | ||||
| Nurse | 18 | 16.92 | 27.3 | 133,500 | 0.957 |
Physician | 15 | 17.10 | ||||
| Nurse | 18 | 17.33 | 24.2 | 141,000 | 0.845 |
Physician | 15 | 16.60 | ||||
| Nurse | 18 | 16.83 | 21.2 | 132,000 | 0.929 |
Physician | 15 | 17.20 | ||||
| Nurse | 18 | 17.25 | 18.2 | 139,500 | 0.873 |
Physician | 15 | 16.70 | ||||
| Nurse | 18 | 15.83 | 15.2 | 114,000 | 0.464 |
Physician | 15 | 18.40 | ||||
| Nurse | 18 | 17.17 | 12.1 | 138,000 | 0.929 |
Physician | 15 | 16.80 | ||||
| Nurse | 18 | 15.75 | 9.1 | 112,500 | 0.421 |
Physician | 15 | 18.50 | ||||
| Nurse | 18 | 17.08 | 6.1 | 136,500 | 0.957 |
Physician | 15 | 16.90 |
Recommendation | Healthcare Professional (N = 33) | N | Mean Rank | Response Rate for Developed Recommendation (%) | Mann-Whitney U-Test | p Value |
---|---|---|---|---|---|---|
| Nurse | 18 | 16.25 | 78.8 | 121,500 | 0.630 |
Physician | 15 | 17.90 | ||||
| Nurse | 18 | 17.08 | 72.7 | 136,500 | 0.957 |
Physician | 15 | 16.90 | ||||
| Nurse | 18 | 17.08 | 72.7 | 136,500 | 0.957 |
Physician | 15 | 16.90 | ||||
| Nurse | 18 | 17.00 | 66.7 | 135,000 | 1.000 |
Physician | 15 | 17.00 | ||||
| Nurse | 18 | 20.58 | 60.6 | 199,500 | 0.018 |
Physician | 15 | 12.70 | ||||
| Nurse | 18 | 15.50 | 57.6 | 108,000 | 0.343 |
Physician | 15 | 18.80 | ||||
| Nurse | 18 | 15.42 | 51.6 | 106,500 | 0.307 |
Physician | 15 | 18.90 | ||||
| Nurse | 18 | 15.33 | 45.5 | 105,000 | 0.290 |
Physician | 15 | 19.00 | ||||
| Nurse | 18 | 19.00 | 45.5 | 171,000 | 0.202 |
Physician | 15 | 14.60 | ||||
| Nurse | 18 | 15.75 | 42.4 | 112,500 | 0.421 |
Physician | 15 | 18.50 | ||||
| Nurse | 18 | 17.08 | 39.4 | 136,500 | 0.957 |
Physician | 15 | 16.90 | ||||
| Nurse | 18 | 17.92 | 33.3 | 151,500 | 0.556 |
Physician | 15 | 15.90 | ||||
| Nurse | 18 | 16.92 | 27.3 | 133,500 | 0.957 |
Physician | 15 | 17.10 | ||||
| Nurse | 18 | 15.92 | 21.2 | 115,500 | 0.486 |
Physician | 15 | 18.30 | ||||
| Nurse | 18 | 16.83 | 21.2 | 132,000 | 0.929 |
Physician | 15 | 17.20 | ||||
| Nurse | 18 | 16.33 | 18.2 | 123,000 | 0.682 |
Physician | 15 | 17.80 | ||||
| Nurse | 18 | 15.42 | 18.2 | 106,500 | 0.307 |
Physician | 15 | 18.90 | ||||
| Nurse | 18 | 17.67 | 15.2 | 147,000 | 0.682 |
Physician | 15 | 16.20 | ||||
| Nurse | 18 | 16.75 | 15.2 | 130,500 | 0.873 |
Physician | 15 | 17.30 | ||||
| Nurse | 18 | 17.67 | 15.2 | 147,000 | 0.682 |
Physician | 15 | 16.20 | ||||
| Nurse | 18 | 17.17 | 12.1 | 138,000 | 0.929 |
Physician | 15 | 16.80 | ||||
| Nurse | 18 | 17.17 | 12.1 | 138,000 | 0.929 |
Physician | 15 | 16.80 | ||||
| Nurse | 18 | 15.33 | 12.1 | 105,000 | 0.290 |
Physician | 15 | 19.00 | ||||
| Nurse | 18 | 15.75 | 9.1 | 112,500 | 0.421 |
Physician | 15 | 18.50 | ||||
| Nurse | 18 | 16.17 | 6.1 | 120,000 | 0.605 |
Physician | 15 | 18.00 | ||||
| Nurse | 18 | 16.17 | 6.1 | 120,000 | 0.605 |
Physician | 15 | 18.00 | ||||
| Nurse | 18 | 17.50 | 3.0 | 144,000 | 0.762 |
Physician | 15 | 16.40 | ||||
| Nurse | 18 | 17.00 | 0 | 136,000 | 1.000 |
Physician | 15 | 17.00 |
Recommendation | Healthcare Professional (N = 75) | N | Mean Rank | Response Rate for Developed Recommendation (%) | Mann- Whitney U-Test | p Value |
---|---|---|---|---|---|---|
| Nurse | 46 | 38.71 | 86.7 | 699,500 | 0.548 |
Physician | 29 | 36.88 | ||||
| Nurse | 46 | 37.15 | 76.0 | 628,000 | 0.566 |
Physician | 29 | 39.34 | ||||
| Nurse | 46 | 40.73 | 74.7 | 792,500 | 0.070 |
Physician | 29 | 33.67 | ||||
| Nurse | 46 | 37.78 | 73.3 | 657,000 | 0.887 |
Physician | 29 | 38.34 | ||||
| Nurse | 46 | 42.12 | 65.3 | 856,500 | 0.012 |
Physician | 29 | 31.47 | ||||
| Nurse | 46 | 40.70 | 50.7 | 791,000 | 0.119 |
Physician | 29 | 33.72 | ||||
| Nurse | 46 | 38.57 | 49.3 | 693,000 | 0.744 |
Physician | 29 | 37.10 | ||||
| Nurse | 46 | 41.33 | 48.0 | 820,000 | 0.054 |
Physician | 29 | 32.72 | ||||
| Nurse | 46 | 38.70 | 45.3 | 699,000 | 0.686 |
Physician | 29 | 36.90 | ||||
| Nurse | 46 | 36.88 | 42.7 | 615,500 | 0.513 |
Physician | 29 | 39.78 | ||||
| Nurse | 46 | 36.01 | 36.0 | 575,500 | 0.231 |
Physician | 29 | 41.16 | ||||
| Nurse | 46 | 38.53 | 25.3 | 691,500 | 0.723 |
Physician | 29 | 37.16 | ||||
| Nurse | 46 | 38.03 | 24.0 | 668,500 | 0.982 |
Physician | 29 | 37.95 | ||||
| Nurse | 46 | 38.85 | 24.0 | 706,000 | 0.566 |
Physician | 29 | 36.66 | ||||
| Nurse | 46 | 36.72 | 22.7 | 608,000 | 0.376 |
Physician | 29 | 40.03 | ||||
| Nurse | 46 | 37.85 | 21.3 | 660,000 | 0.915 |
Physician | 29 | 38.24 | ||||
| Nurse | 46 | 38.92 | 13.3 | 709,500 | 0.432 |
Physician | 29 | 36.53 |
Recommendation | Healthcare Platform (N = 108) | N | Mean Rank | Response Rate for Developed Recommendation (%) | Mann-Whitney U-Test | p Value |
---|---|---|---|---|---|---|
| PHCs | 75 | 52.20 | 82.4 | 1410,000 | 0.081 |
RH | 33 | 59.73 | ||||
| PHCs | 75 | 54.96 | 76.9 | 1203,000 | 0.753 |
RH | 33 | 53.45 | ||||
| PHCs | 75 | 53.18 | 72.2 | 1336,500 | 0.395 |
RH | 33 | 57.50 | ||||
| PHCs | 75 | 50.90 | 66.7 | 1507,500 | 0.027 |
RH | 33 | 62.68 | ||||
| PHCs | 75 | 54.22 | 64.8 | 1258,500 | 0.866 |
RH | 33 | 55.14 | ||||
| PHCs | 75 | 56.14 | 53.7 | 1114,500 | 0.342 |
RH | 33 | 50.77 | ||||
| PHCs | 75 | 55.58 | 50.0 | 1156,500 | 0.533 |
RH | 33 | 52.05 | ||||
| PHCs | 75 | 53.86 | 48.1 | 1285,000 | 0.711 |
RH | 33 | 55.95 | ||||
| PHCs | 75 | 56.46 | 46.3 | 1090,500 | 0.256 |
RH | 33 | 50.05 | ||||
| PHCs | 75 | 52.52 | 41.7 | 1386,000 | 0.246 |
RH | 33 | 59.00 | ||||
| PHCs | 75 | 51.06 | 29.6 | 1495,500 | 0.030 |
RH | 33 | 62.32 | ||||
| PHCs | 75 | 57.04 | 28.7 | 1047,000 | 0.105 |
RH | 33 | 48.73 | ||||
| PHCs | 75 | 57.98 | 27.8 | 976,500 | 0.025 |
RH | 33 | 46.59 | ||||
| PHCs | 75 | 55.32 | 26.9 | 1176,000 | 0.593 |
RH | 33 | 52.64 | ||||
| PHCs | 75 | 53.76 | 21.3 | 1293,000 | 0.602 |
RH | 33 | 56.18 | ||||
| PHCs | 75 | 52.54 | 20.4 | 1384,500 | 0.160 |
RH | 33 | 58.95 | ||||
| PHCs | 75 | 53.30 | 11.1 | 1327,500 | 0.270 |
RH | 33 | 57.23 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Forrester, M.; Breitenfeld, L.; Castelo-Branco, M.; Aperta, J. The Effects of the COVID-19 Pandemic in Oncology Patient Management. Int. J. Environ. Res. Public Health 2022, 19, 9041. https://doi.org/10.3390/ijerph19159041
Forrester M, Breitenfeld L, Castelo-Branco M, Aperta J. The Effects of the COVID-19 Pandemic in Oncology Patient Management. International Journal of Environmental Research and Public Health. 2022; 19(15):9041. https://doi.org/10.3390/ijerph19159041
Chicago/Turabian StyleForrester, Mario, Luiza Breitenfeld, Miguel Castelo-Branco, and Jorge Aperta. 2022. "The Effects of the COVID-19 Pandemic in Oncology Patient Management" International Journal of Environmental Research and Public Health 19, no. 15: 9041. https://doi.org/10.3390/ijerph19159041
APA StyleForrester, M., Breitenfeld, L., Castelo-Branco, M., & Aperta, J. (2022). The Effects of the COVID-19 Pandemic in Oncology Patient Management. International Journal of Environmental Research and Public Health, 19(15), 9041. https://doi.org/10.3390/ijerph19159041